Brevital Sodium 500 mg/vial for Injection

• Presence of particulate matter identified as cellulose
• Company: Par Health
• Drugs
• FDA
• October 8, 2026

Product details

• Brevital Sodium 500 mg/vial for Injection

Company announcement

Par Health is recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) due to particulate matter identified as cellulose.

The product was distributed nationwide to wholesalers between July 8, 2025, and May 11, 2026.

No adverse events have been reported to date.

Risk:

Administration of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP), found to contain particulate matter, has a reasonable probability of causing life-threatening adverse health consequences including pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or inflammation of the walls of veins, which may lead to clotting.

Impacted states: Nationwide

Products:

- Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Lot 86930

- Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Lot 88623

Contact

For more information, call 1-844-774-1187 or email rxrecalls@inmar.com.

View the original FDA notice

Browse all recalls

Related recalls

• Argatroban Injection 250 mg/2.5 mL (100 mg/mL)
• Glutathione Injection
• Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) for Intravenous Infusion
• 0.9% Sodium Chloride Injection, USP, 100 mL
• Compounded Glutathione 200 mg/mL 30 mL multidose vial; Myer’s Cocktail 30 mL multidose vial; Tri-Immune Boost 30 mL multidose vial